1. Introduction {#sec1}
===============

Lung cancer remains a principal cause of death worldwide. However, there has been remarkable progress in the development of treatment strategies for lung cancer, particularly adenocarcinoma, over the past 15 years. Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are key drugs for *EGFR* mutation-positive non-small cell lung cancers (NSCLCs), most patients become resistant to the drugs within 1 year, which has become an important issue. Several resistance mechanisms were recently clarified, including an *EGFR* T790M secondary mutation, small cell lung cancer (SCLC) transformation, and activation of bypass signaling \[[@bib1],[@bib2]\]. Here, we report a case with an *EGFR* T790M mutation detected during chemotherapy for SCLC transformation of gefitinib resistance that responded to osimertinib.

2. Case {#sec2}
=======

A 76-year-old woman visited The Cancer Institute Hospital of Japanese Foundation for Cancer Research because of left-side lateral chest pain. Computed tomography (CT) showed a tumor shadow in her left lung. After several examinations and a tumor biopsy, progressive lung adenocarcinoma harboring an *EGFR-L858R* mutation was diagnosed. Gefitinib was administered as a first-line treatment, which had a clinically significant response lasting for 20 months. CT performed again revealed re-progression of the primary lesion in the left upper lobe. A re-biopsy of the primary lesion during gefitinib treatment showed SCLC transformation, which was supported by positive immunohistochemical (IHC) staining of the neural cell adhesion molecule (NCAM) and synaptophysin, with an *EGFR* L858R mutation, but not T790M ([Table 1](#tbl1){ref-type="table"}). After discontinuation of gefitinib, four cycles of cisplatin and etoposide were started as a second-line therapy, which resulted in a response that lasted for 5 months. Then, because re-progression was observed during the second-line treatment, chemotherapy and immunotherapy were initiated with two cycles of amrubicin, two cycles of nivolumab, and two cycles of CPT-11 administered over a 6-month period ([Fig. 1](#fig1){ref-type="fig"}A). A follow-up CT showed worsening of the primary lesion ([Fig. 1](#fig1){ref-type="fig"}B) accompanied by an increase in plasma carcinoembryonic antigen (CEA), which is a known tumor marker of adenocarcinoma. A second re-biopsy via bronchoscopy of the primary lesion showed adenocarcinoma, which was supported by negative IHC staining of NCAM, synaptophysin, and chromogranin A. At this point, mutation analysis revealed the presence of *EGFR* L858R and T790M mutations. Thus, osimertinib was started at a dose of 80 mg per day, which resulted in rapid and dramatic clinical improvement with a decrease in serum CEA levels ([Fig. 1](#fig1){ref-type="fig"}C). Serial CT after initiation of osimertinib showed a partial response that lasted almost 3 months ([Fig. 1](#fig1){ref-type="fig"}B).Fig. 1Panel A shows the series of treatments the patient received for metastatic non-small cell lung cancer as well as the duration of each treatment. Panel B shows computed tomographic images of the primary left upper lung tumor before gefitinib administration, when the disease subsequently relapsed at 20 months, and during the response to combination chemotherapy of cisplatin and etoposide. After treatment with several chemotherapy agents and immunotherapy sequentially, the primary lesion enlarged and a metastatic lesion appeared in right lower lung after CPT-11 therapy (marked with arrows). A radiologic response to osimertinib was noted after 4 weeks of treatment. Panel C shows serial monitoring of CEA levels and pro-GRP levels before and after retreatment with osimertinib, which was initiated at a dose of 80 mg per day on day 1. The CEA level decreased with tumor shrinkage. Panel D shows the results of histology. (1) A tissue section from pleural dissemination (hematoxylin and eosin stained, magnification ×400) at first diagnosis shows metastatic adenocarcinoma. (2) Tissue section of re-biopsy from the left upper lung after resistance to gefitinib (hematoxylin and eosin stained, magnification ×400) shows small cell carcinoma. (3) Tissue section of second re-biopsy from the same lesion at resistance to sequential chemotherapy for SCLC (hematoxylin and eosin stained, magnification ×400) shows adenocarcinoma.Fig. 1Table 1Tumor biopsy tissue finding of Histology, IHC stain and EGFR mutation status.Table 1Before GefitinibResistance GefitinibBefore OsimertinibHistologyAdenocarcinomaSmall cell carcinomaAdenocarcinomaIHC stainTTF-1 (clone 8G7G3/1, DAKO)+++NCAM (clone 1B6, Leica)--+--SYN (clone 27G12, Leica)--+--CGA (clone DAK-A3, DAKO)NENE--*EGFR* mutation statusL858R+++T790M----+[^1]

3. Discussion {#sec3}
=============

Previous reports have identified several mechanisms of acquired resistance to EGFR-TKIs. The most frequent acquired resistance is the *EGFR* T790M point mutation, which occurs in 50%--65% of resistant cases, and SCLC transformation in 3%--14% \[[@bib3],[@bib4]\]. Generally, a T790M secondary mutation develops with ongoing ATP competitive inhibition or T790M, which can be detected in a small proportion of tumors before treatment with EGFR-TKIs, with increasing frequency post-treatment, consistent with ongoing selection of T790M clones upon EGFR-TKI \[[@bib5]\]. Third-generation TKIs, such as osimertinib, demonstrated efficacy for patients who developed resistance to first or second generation EGFR-TKIs due to T790M mutation \[[@bib6]\].

Several case reports have described SCLC transformation from adenocarcinoma with an *EGFR* mutation after resistance to EGFR-TKI. However, the mechanism of SCLC transformation remains unclear. Oser et al. proposed two hypotheses of SCLC transformation \[[@bib2]\]. The first is that type II alveolar cells, the origin of some *EGFR*-mutant adenocarcinomas, also have the potential to become SCLC, which was discovered in a pre-clinical study. The second is a combined SCLC and NSCLC histology at first diagnosis, where each histology becomes dominant alternately in response to anti-cancer drugs. SCLC with an *EGFR* mutation may be sensitive to standard chemotherapy \[[@bib4]\].

Our patient had an *EGFR* L858R mutation and received multiple treatments, including first generation EGFR-TKIs, chemotherapy, and third generation EGFR-TKIs. Several types of EGFR resistance developed during treatment. The first resistance was SCLC transformation with an L858R mutation during gefitinib treatment and the second resistance was an unexpected *EGFR-T790M* mutation identified during chemotherapy. This acquired resistance conferred sensitivity to osimertinib, however its short response duration might have been cause by a dominant histological change like a pendulum. Over the course of the treatment, serial repeated biopsies provided clinically relevant and invaluable insights. Although the developing mechanism of *EGFR* T790M mutation without last-minute EGFR-TKI exposure is unclear, we considered that *EGFR* T790M mutated cells might have been involved in SCLC transformation at first resistance, but this mutation could not be detected because of the small biopsy sample and was detected after chemotherapy. Indeed, the phenotype of the second re-biopsy sample again changed to adenocarcinoma. However, it remains unclear why the proportion of cells with the *EGFR* T790M mutation had increased without ongoing selection of T790M clones upon EGFR-TKI.

This case suggested that serial biopsies are necessary to choose an effective treatment strategy and testing for the T790M mutation should be performed even after SCLC transformation.
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[^1]: IHC Immunohistochemical, TTF-1 Thyroid Transcription Factor-1, NCAM Neural cell adhesion molecule, SYN Synaptophysin, CGA Chromogranin A, EGFR epidermal growth factor receptor, NE not evaluated.
